After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

HHS secretary nominee Robert F. Kennedy Jr. is one step closer to confirmation as the Senate Finance Committee voted on ...

Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

Before the Senate's confirmation vote on President Donald Trump’s pick for secretary of the Department of Health and Human ...

When it comes to the safe use of synthetic opioids like fentanyl, precise dosing of the powerful pain meds is key. Now, ...

Among its various international efforts, USAID works to strengthen global supply chains and promote access to essential ...

While much of Valneva's focus these days is centered on its landmark vaccine for chikungunya virus, the French immunization ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

“A 25% tariff on Canada and Mexico threatens to upend the very supply chains that have made U.S. manufacturing more ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. | Novartis has become ...